9.21

2.39% -0.23

Theravance Biopharma Inc (TBPH)

Overview News Price History Option Chain Financials Discussions Forecast

Theravance Biopharma Inc stock is traded at $9.21, with a volume of 47,458. It is down -2.39% in the last 24 hours and down -2.80% over the past month. Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Previous Close:

$9.44

Open:

$9.39

24h Volume:

47,458

Relative Volume:

0.23

Market Cap:

$457.60M

Revenue:

$62.02M

Net Income/Loss:

$-45.65M

P/E Ratio:

-10.01

EPS:

-0.92

Net Cash Flow:

$-9.60M

1W Performance:

-5.11%

1M Performance:

-2.80%

6M Performance:

+13.20%

1Y Performance:

+4.71%

1-Day Range:

$9.155

$9.39

1-Week Range:

$9.12

$9.91

52-Week Range:

$7.44

$10.90

Theravance Biopharma Inc Stock (TBPH) Company Profile

Name

Theravance Biopharma Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

650-808-6000

Address

UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

TBPH's Discussions on Twitter

Compare TBPH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TBPH Theravance Biopharma Inc	9.21	457.60M	62.02M	-45.65M	-9.60M	-0.92
VRTX Vertex Pharmaceuticals Inc	498.33	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	678.01	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	577.05	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	240.72	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.13	26.76B	3.32B	-860.46M	-1.04B	-8.32

Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-06-24	Downgrade	Leerink Partners	Outperform → Market Perform
Apr-12-24	Initiated	BTIG Research	Buy
Jan-08-24	Downgrade	Evercore ISI	Outperform → In-line
May-23-22	Initiated	SVB Leerink	Outperform
Nov-05-21	Upgrade	JP Morgan	Underweight → Neutral
Sep-15-21	Downgrade	JP Morgan	Overweight → Underweight
Aug-25-21	Downgrade	Morgan Stanley	Overweight → Underweight
Aug-24-21	Downgrade	Cowen	Outperform → Market Perform
Oct-14-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-07-20	Initiated	JP Morgan	Overweight
Jun-15-20	Initiated	Morgan Stanley	Equal-Weight
May-13-20	Initiated	Cowen	Outperform
Jan-08-20	Reiterated	H.C. Wainwright	Buy
Nov-06-19	Upgrade	Robert W. Baird	Underperform → Neutral
Oct-29-19	Initiated	H.C. Wainwright	Buy
Mar-29-18	Resumed	Piper Jaffray	Overweight
Aug-17-17	Initiated	Evercore ISI	Outperform
Jun-16-17	Initiated	Cantor Fitzgerald	Overweight
May-11-17	Reiterated	Needham	Buy
Dec-21-16	Initiated	Needham	Buy
Nov-03-16	Initiated	Piper Jaffray	Overweight
Oct-12-16	Downgrade	Robert W. Baird	Neutral → Underperform
Aug-03-16	Downgrade	BofA/Merrill	Neutral → Underperform
Jun-20-16	Initiated	Guggenheim	Buy
Jun-20-16	Reiterated	Leerink Partners	Outperform
May-12-16	Initiated	Leerink Partners	Outperform
May-05-16	Downgrade	BofA/Merrill	Buy → Neutral
Feb-03-15	Upgrade	Robert W. Baird	Underperform → Neutral

View All

Theravance Biopharma Inc Stock (TBPH) Latest News

Mar 10, 2025

Theravance Biopharma: Clinical Progress Is Not Enough To Make It Attractive - Seeking Alpha

Mar 10, 2025

Mar 08, 2025

Rhumbline Advisers Sells 3,110 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World

Mar 08, 2025

Mar 07, 2025

Theravance Biopharma (NASDAQ:TBPH) Share Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat

Feb 28, 2025

Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - MarketBeat

Feb 28, 2025

HC Wainwright Reiterates Buy Rating for Theravance Biopharma (NASDAQ:TBPH) - MarketBeat

Feb 28, 2025

Theravance Biopharma Reports Strong Q4 2024 Earnings - TipRanks

Feb 28, 2025

Investor Network: Theravance Biopharma Inc to Host Earnings Call - ACCESS Newswire

Feb 28, 2025

Research Analysts Issue Forecasts for TBPH FY2024 Earnings - Defense World

Feb 28, 2025

Feb 27, 2025

Theravance Biopharma (NASDAQ:TBPH) Releases Earnings Results, Misses Estimates By $0.26 EPS - MarketBeat

Feb 27, 2025

Theravance's Q4 Loss In Line With Estimates, Sales Beat - Yahoo Finance

Feb 27, 2025

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 27, 2025

FY2024 Earnings Forecast for TBPH Issued By HC Wainwright - MarketBeat

Feb 27, 2025

HC Wainwright Reiterates “Buy” Rating for Theravance Biopharma (NASDAQ:TBPH) - Defense World

Feb 27, 2025